Array BioPharma (ARRY) reported 44% jump in second-quarter revenue to $82.5 million, driven by higher product sales and recognition of $40 million of milestone revenue from Loxo Oncology. The top line came in well above street projection of $49.02 million.
Net loss was cut down to 5 cents per share from 17 cents per share last year. Analysts were expecting a loss of 16 cents per share.
ARRY shares popped 3.2% during pre-market trading post the earnings announcement. The stock has gained 35% in the trailing 12 months.
CEO Ron Squarer said, “We continue to be pleased with demand following the US launch of BRAFTOVI + MEKTOVI for patients with BRAF-mutant metastatic melanoma, which delivered $22.7 million in net product sales during the second commercial quarter.”
BRAFTOVI + MEKTOVI net product sales soared 62% in the US compared to the prior sequential quarter. The combination has also been launched in Germany, Austria, the Netherlands, and the United Kingdom
Autodesk, Inc. (NASDAQ: ADSK) today reported its fourth quarter financial results for the period ended January 31, 2021. Net income for the fourth quarter was $911.3 million, or $4.10 per
Beyond Meat (NASDAQ: BYND), a specialist in plant-based meat substitutes, Thursday reported a wider loss for the fourth quarter, despite an increase in revenues. The numbers also missed the consensus
Virgin Galactic (NYSE: SPCE) reported fourth-quarter 2020 financial results after the regular market hours on Thursday. The space tourism company reported zero revenue in the fourth quarter, compared to $529,000